Clinical Trials Browser

Has results × Melanoma × Dactinomycin × Clear all

NCT01323517 2018-05-15

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Phase 2 Completed

26 enrolled 11 charts

Melanoma